Last updated on April 2019

Umbilical Cord Blood Transplantation From Unrelated Donors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Leukemia | Solid Tumor | Acute Leukemia | Metabolic disorder | Immunodeficiency | Multiple Myeloma | Aplastic Anemia | Congenital Hematological Disorder | Lymphoma | Preleukemia | MYELODYSPLASTIC SYNDROME
  • Age: Between 1 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Appropriate diagnosis: Patients must have a disease or syndrome amenable to therapy with hematopoietic stem cell transplantation. Diagnoses include, but are not limited
  • Congenital and Other Non-malignant Disorders:
  • Immunodeficiency disorders (e.g. Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome)
  • Congenital hematopoietic stem cell defects (e.g. Chediak-Higashi Syndrome, Congenital Osteopetrosis, Osteogenesis Imperfecta)
  • Metabolic disorders (e.g. Hurler's Syndrome)
  • Severe aplastic anemia
  • High-Risk Leukemia:
  • Acute Myelogenous Leukemia
  • Refractory to standard induction therapy (more than 1 cycle required to achieve remission)
  • Recurrent (in CR 2)
  • Treatment-related AML or MDS
  • Evolved from myelodysplastic syndrome
  • Presence of FLT3 abnormalities
  • FAB M6 or M7
  • Adverse cytogenetics
  • Myelodysplastic Syndrome
  • Acute Lymphoblastic Leukemia including T lymphoblastic leukemia:
  • Refractory to standard induction therapy (time to CR >4 weeks)
  • Recurrent (in CR 2)
  • WBC count >30,000/mcL at diagnosis
  • Age >30 at diagnosis
  • Adverse cytogenetics, such as t(9:22), t(1:19), t(4:11), and other MLL rearrangements.
  • Chronic Myelogenous Leukemia in accelerated phase or blast crisis
  • Biphenotypic or undifferentiated leukemia
  • Burkitt's leukemia or lymphoma
  • Lymphoma:
  • Large cell, Mantle cell, Hodgkin lymphoma refractory or recurrent, chemo-sensitive, and ineligible for an autologous stem cell transplant or previously treated with autologous SCT
  • Marginal zone or follicular lymphoma that is progressive after at least two prior therapies
  • Multiple Myeloma, recurrent following high-dose therapy and autologous SCT or ineligible for an autologous HSCT
  • Solid tumors, with efficacy of allogeneic HSCT demonstrated for the specific disease and disease status
  • Adequate organ function:
  • Cardiac - LVEF >45%, or shortening fraction >25%, Absence of congestive heart failure or conduction disturbances with high risk for sudden death
  • Pulmonary - DLCO (corrected for hemoglobin), FEV1 and FVC 50% predicted;
  • Renal - serum Cr < 1.5 times the upper limit of normal for age or GFR 50 ml/min/1.73m2
  • Hepatic - total bilirubin level < 2 times the upper limit of normal (except for patients with Gilbert's syndrome or hemolysis); if the primary disease process is causal, this criterion will be reconsidered. ALT, AST, and Alkaline phosphatase 5 times upper limit of normal.
  • Performance Status Karnofsky or Lansky score 70%.
  • Informed Consent must be obtained prior to initiating conditioning therapy.
  • Receipt of viable cord blood product(s), single or dual, must be confirmed with the stem cell processing laboratory prior to initiating conditioning therapy.

Exclusion Criteria:

  • Availability of 10/10 or 9/10 HLA-matched related or unrelated donor within a reasonable timeframe dictated by the clinical urgency of the transplant
  • Autologous HSCT < 6 months prior to proposed UCB transplant
  • Pregnant or breast feeding
  • Current uncontrolled infection
  • Evidence of HIV infection or positive HIV serology

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.